25
Participants
Start Date
September 30, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Nonacog alfa
Period 1: During on-demand period, dosing at the discretion of investigator.
Nonacog alfa
Period 2: During the prophylaxis period, 100 IU/kg once weekly
UMBAL Sveti Georgi, Klinika po hematologia, Plovdiv
University Hospital Center Zagreb, Zagreb
Instituto Biomedico de Investigacion A.C., Aguascalientes
Hospital Tengku Ampuan Afzan, Kuantan
Gaziantep Universitesi Tip Fakultesi Sahinbey Arastirma ve Uygulama Hastanesi Hematoloji Poliklinigi, Gaziantep
Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bilim Dali, Fatih
Ege Universitesi Tip Fakultesi, Bornova/Izmir
Erciyes Universitesi Tip Fakultesi, Kayseri
Erciyes Universitesi Tip Fakultesi Hastaneleri M. Kemal Dedeman Onkoloji Hastanesi, Kayseri̇, Erciyes
National Blood Centre, Kuala Lumpur
Hospital y Clinica OCA, Monterrey
Singapore General Hospital, Singapore
The Ottawa Hospital, Ottawa
Nzoz Triclinium, Warsaw
Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw
Eulji University Hospital, Daejeon
Hacettepe Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bolumu, Ankara
Lead Sponsor
Pfizer
INDUSTRY